Why Quest Diagnostics Stock Is Back in Focus

Quest Diagnostics (DGX) is back on investor watchlists after the company moved to integrate its Haystack MRD ctDNA and Comprehensive Genomic Profiling cancer tests directly into Flatiron Health’s OncoEMR platform.

This pilot, launched with American Oncology Network and other community providers, lets clinicians at 1,600 cancer care locations order select Quest oncology tests inside their existing electronic health record workflows, with a broader rollout planned later in the year.

Quest Diagnostics shares have been supported by solid recent momentum, with a 1 month share price return of 8.04% and a year to date share price return of 21.23%, alongside a 1 year total shareholder return of 28.44% that points to steadily improving sentiment rather than a sudden spike.

If this oncology integration has you thinking about where healthcare and technology intersect, it could be a good moment to scan for other opportunities in the sector using the 39 healthcare AI stocks.

After Quest Diagnostics' strong recent run and fresh oncology integration, the debate now turns to valuation. Is there still meaningful upside ahead, or has most of the opportunity already shown up in the share price?

Most Popular Narrative: 5.7% Undervalued

On the most followed view of Quest Diagnostics, a fair value of $223.44 sits modestly above the last close at $210.68, which keeps the focus on what is driving that gap rather than on a dramatic mispricing.

Ongoing growth in advanced and preventive testing including cardiometabolic, autoimmune, brain health, oncology, and women's/reproductive diagnostics as well as robust demand from functional medicine and wellness-focused consumers, are driving higher test volumes and increasing test-per-requisition, which supports both revenue growth and margin expansion.

Curious what kind of revenue trajectory, margin lift, and future earnings multiple are baked into that $223.44 figure? The underlying narrative ties steady test volume expansion, improving profitability, and a specific earnings profile together in a way that may surprise you.

Result: Fair Value of $223.44 (UNDERVALUED)

However, for Quest Diagnostics this story can shift quickly if PAMA reimbursement cuts bite harder than expected, or if wage and technology costs rise faster than earnings.

Next Steps

Given the mix of optimism and concern around Quest Diagnostics, this is a good time to review the data yourself, act promptly, and weigh both sides using the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Quest Diagnostics?

If the Quest Diagnostics story has sharpened your focus, do not stop here. Broaden your watchlist with other clear, data driven ideas before the market moves on.

• Target steady compounding potential by reviewing companies with resilient cash flows and quality fundamentals using the 47 high quality undervalued stocks.
• Strengthen your income stream by checking out companies offering higher yields and consistent payouts through the 8 dividend fortresses.
• Sleep easier at night by screening for companies with lower risk profiles and sturdier financials via the 82 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.